Tipranavir/Ritonavir

DRUG3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Boehringer Ingelheim, Johns Hopkins University

Conditions

HIV Infections

Phase 1

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

CompletedNCT00344123

Johns Hopkins UniversityHIV Infections

Start: 2007-02-28End: 2008-05-31Updated: 2016-02-04

Phase 3

Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

CompletedNCT00144287

Boehringer IngelheimHIV Infections

Start: 2004-05-31End: 2006-04-30Updated: 2013-11-05

Unknown Phase

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

CompletedNCT00042289

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2003-06-09End: 2020-09-30Updated: 2025-12-02

Related Papers

Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.

2021-02-1717 citations

Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum

The Journal of Clinical Pharmacology2018-10-2511 citations

Efavirenz Pharmacokinetics during Pregnancy and Infant Washout

Antiviral Therapy2018-02-0122 citations

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

Frontiers in Pharmacology2016-08-0419 citations

Maraviroc Pharmacokinetics in HIV-1–Infected Pregnant Women

Clinical Infectious Diseases2015-07-2216 citations

Raltegravir pharmacokinetics during pregnancy.

2014-12-0155 citations

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.

2014-09-257 citations